Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00175916 · ClinicalTrials.gov registry record · Phase 3
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 853
- Enrollment target
NCT00175916: Completed Phase 3 study, sponsored by UCB Pharma.
NCT00175916 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 853 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00175916, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 853 participants
- Enrollment target
Study Summary
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).
Primary Outcome
Treatment-emergent adverse events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.
Interventions
- DRUG Brivaracetam (ucb 34714)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 853 participants |
| Start Date | 2005-09 |
| Est. Completion | 2019-05 |
| Phase | Phase 3 |
What the finished NCT00175916 record still lists
NCT00175916 is an interventional study that assigns participants to a tested intervention. The registered 853 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 1 intervention - of which Brivaracetam (ucb 34714) is the first listed.
NCT00175916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00175916 about?
NCT00175916 is a clinical study titled "Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy". This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjec...
What is the current status of trial NCT00175916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 853 participants. The study started on 2005-09. Estimated completion is 2019-05.
What interventions are being tested in trial NCT00175916?
The interventions under investigation include: Brivaracetam (ucb 34714) (DRUG).
Who is sponsoring clinical trial NCT00175916?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00175916's enrollment target sits among peer trials
853 385th of 2000 higher than 1,616 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia